I Jolanda M de Vries Selected Research

Monophenol Monooxygenase (Tyrosinase)

3/2020	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial.
7/2016	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
7/2016	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
3/2016	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
1/2016	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
1/2016	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.
8/2015	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.
11/2014	Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
3/2013	Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells.
9/2011	Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

I Jolanda M de Vries Research Topics

Disease

99	Neoplasms (Cancer) 06/2022 - 09/2002
37	Melanoma (Melanoma, Malignant) 01/2022 - 11/2003
7	Hypersensitivity (Allergy) 11/2019 - 11/2003
3	Urinary Bladder Neoplasms (Bladder Cancer) 06/2022 - 11/2012
3	Inflammation (Inflammations) 10/2021 - 01/2005
3	Prostatic Neoplasms (Prostate Cancer) 01/2020 - 01/2014
3	Infections 01/2018 - 01/2010
3	Squamous Cell Carcinoma of Head and Neck 01/2017 - 03/2005
3	Communicable Diseases (Infectious Diseases) 11/2011 - 04/2010
2	Rare Diseases (Rare Disease) 01/2022 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2021 - 05/2012
2	Ovarian Neoplasms (Ovarian Cancer) 01/2018 - 01/2018
2	Virus Diseases (Viral Diseases) 11/2012 - 07/2006
2	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2010 - 04/2008
2	Brain Neoplasms (Brain Tumor) 08/2009 - 07/2008
1	Gestational Trophoblastic Disease (Trophoblastic Neoplasms, Gestational) 01/2022
1	Choriocarcinoma 01/2022
1	Hydatidiform Mole (Molar Pregnancy) 01/2022
1	Testicular Neoplasms (Testicular Cancer) 01/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 10/2021
1	Microsatellite Instability 05/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021
1	Colitis 01/2021
1	Heart Failure 03/2020
1	Ascites 01/2018
1	Fatigue 01/2018
1	Peritonitis 01/2018
1	Turcot syndrome 10/2017
1	Meningoencephalitis 03/2017
1	Colorectal Neoplasms (Colorectal Cancer) 10/2016
1	Lymphatic Metastasis 01/2016
1	Uveal melanoma 11/2014

Drug/Important Bio-Agent (IBA)

37	AntigensIBA 01/2022 - 11/2003
24	VaccinesIBA 01/2022 - 09/2002
16	Peptides (Polypeptides)IBA 01/2018 - 11/2003
15	Monophenol Monooxygenase (Tyrosinase)IBA 03/2020 - 11/2003
12	Neoplasm Antigens (Tumor Antigens)IBA 01/2020 - 09/2002
9	Messenger RNA (mRNA)IBA 03/2020 - 03/2005
9	keyhole-limpet hemocyanin (keyhole limpet hemocyanin)IBA 01/2017 - 11/2003
8	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2016
8	Proteins (Proteins, Gene)FDA Link 01/2018 - 07/2006
7	Cancer VaccinesIBA 01/2021 - 01/2007
6	Cisplatin (Platino)FDA LinkGeneric 06/2022 - 08/2011
6	PlatinumIBA 01/2021 - 08/2011
6	CytokinesIBA 07/2016 - 12/2007
5	LigandsIBA 01/2022 - 04/2008
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2010
3	IpilimumabIBA 01/2022 - 08/2016
3	Interleukin-12 (IL 12)IBA 10/2021 - 03/2005
3	DNA (Deoxyribonucleic Acid)IBA 05/2021 - 04/2011
3	RNA (Ribonucleic Acid)IBA 03/2017 - 07/2009
3	Platinum Compounds (Compounds, Platinum)IBA 01/2017 - 08/2011
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2016 - 07/2012
2	AntibodiesIBA 01/2022 - 03/2012
2	HLA-A Antigens (HLA-A)IBA 01/2022 - 03/2013
2	Protamines (Protamine Sulfate)FDA Link 11/2019 - 03/2017
2	Interferon Type IIBA 01/2018 - 11/2012
2	ChemokinesIBA 11/2017 - 01/2016
2	Death Domain ReceptorsIBA 06/2014 - 08/2011
2	Monoclonal AntibodiesIBA 10/2010 - 01/2007
2	Pattern Recognition ReceptorsIBA 01/2010 - 04/2008
2	ferric oxide (iron oxide)IBA 04/2009 - 11/2005
2	Interleukin-2 (IL2)IBA 01/2009 - 11/2002
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	EpitopesIBA 01/2022
1	Biological ProductsIBA 10/2021
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2021
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 05/2021
1	Trans-Activators (Trans-Acting Factor)IBA 01/2021
1	NanovaccinesIBA 01/2021
1	Granzymes (Granzyme)IBA 01/2020
1	LipidsIBA 01/2018
1	Interferon-gamma (Interferon, gamma)IBA 01/2018
1	Immune Checkpoint ProteinsIBA 01/2018
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 03/2017
1	Melanins (Melanin)IBA 03/2017
1	Combined VaccinesIBA 10/2016
1	VemurafenibIBA 04/2016
1	Dinoprostone (PGE2)FDA Link 03/2016
1	ProteomeIBA 01/2016
1	CD40 Ligand (CD40L)IBA 08/2015
1	Melanoma-Specific AntigensIBA 11/2014
1	HMGB ProteinsIBA 06/2014
1	IGF Type 2 Receptor (Insulin-Like-Growth-Factor II Receptor)IBA 06/2014
1	Carboplatin (JM8)FDA LinkGeneric 06/2014
1	CalreticulinIBA 06/2014
1	Adenosine Triphosphate (ATP)IBA 06/2014
1	sipuleucel-T (APC8015)FDA Link 01/2014

Therapy/Procedure

51	Immunotherapy 01/2022 - 01/2007
25	Therapeutics 01/2022 - 11/2005
6	Drug Therapy (Chemotherapy) 06/2022 - 06/2010
4	Lymph Node Excision (Lymph Node Dissection) 07/2016 - 09/2011
2	Castration 01/2020 - 11/2019
2	Treatment Delay 11/2019 - 02/2011
1	Neoadjuvant Therapy 06/2022
1	Cystectomy 06/2022
1	Radiotherapy 01/2017
1	Chemoradiotherapy 01/2017
1	Intravenous Injections 03/2016
1	Injections 02/2013